Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Galectin Therapeutic (GALT)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
[[ ctrl.chartTitle ]]
Full Chart

Fundamentals

See More
  • Market Capitalization, $K 84,942
  • Shares Outstanding, K 34,670
  • Annual Sales, $ 0 K
  • Annual Income, $ -21,440 K
  • 36-Month Beta 2.45
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 130.88

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.20 +12.27%
on 06/19/17
2.75 -10.18%
on 06/08/17
-0.04 (-1.59%)
since 05/26/17
3-Month
1.96 +26.02%
on 03/29/17
3.68 -32.88%
on 04/10/17
+0.44 (+21.67%)
since 03/28/17
52-Week
0.49 +404.08%
on 11/03/16
3.68 -32.88%
on 04/10/17
+0.98 (+65.77%)
since 06/28/16

Most Recent Stories

More News
Patent for Reducing Inflammatory Response Granted to Galectin Therapeutics

Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that the Company has received notice of allowance for a U.S. Patent for "Galacto-Rhamnogalacturonate...

GALT : 2.47 (+0.82%)
Autoimmune Disease Patent Granted to Galectin Therapeutics

Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that the Company has been issued U.S. Patent 9,649,327 for "Composition of...

GALT : 2.47 (+0.82%)
Galectin Therapeutics launches the Liver Line, an online community and publication on liver health and liver disease

Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced the launch of the Liver Line, an online community and publication on liver...

GALT : 2.47 (+0.82%)
Can The Uptrend Continue for Galectin Therapeutics (GALT)?

Investors certainly have to be happy with Galectin Therapeutics Inc (GALT) and its short term performance

GALT : 2.47 (+0.82%)
Galectin Therapeutics Receives Notice of Japanese Decision to Grant a Composition of Matter Patent for GR-MD-02

Galectin Therapeutics, Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis, skin diseases, and cancer, today announced that the Company has received...

GALT : 2.47 (+0.82%)
Will Henry Schein (HSIC) Deliver a Surprise in Q1 Earnings?

Henry Schein, Inc. (HSIC) is expected to report first-quarter 2017 results on May 2, before the opening bell.

SYRS : 17.71 (+2.79%)
GALT : 2.47 (+0.82%)
HSIC : 184.28 (+0.77%)
HRC : 79.97 (+1.34%)
Can Myriad Genetics (MYGN) Spring a Surprise in Q3 Earnings?

Myriad Genetics, Inc. (MYGN) is scheduled to report third-quarter fiscal 2017 results on May 2, after the closing bell.

SYRS : 17.71 (+2.79%)
GALT : 2.47 (+0.82%)
MYGN : 26.26 (+3.35%)
HRC : 79.97 (+1.34%)
Edward Lifesciences (EW) Q1 Earnings: A Surprise in Store?

Edward Lifesciences Corp. (EW) is scheduled to report first-quarter 2017 earnings results after market close on Apr 25.

SYRS : 17.71 (+2.79%)
EW : 118.39 (+1.08%)
GALT : 2.47 (+0.82%)
HRC : 79.97 (+1.34%)
Can Mead Johnson (MJN) Spring a Surprise in Q1 Earnings?

Mead Johnson Nutrition Company (MJN) is expected to report first-quarter 2017 results on Apr 27, before the opening bell.

MJN : 89.98 (-0.01%)
SYRS : 17.71 (+2.79%)
GALT : 2.47 (+0.82%)
HRC : 79.97 (+1.34%)
ResMed (RMD) Q3 Earnings: Disappointment in the Cards?

ResMed Inc. (RMD) is slated to report third-quarter fiscal 2017 results, after market close on Apr 27.

SYRS : 17.71 (+2.79%)
GALT : 2.47 (+0.82%)
RMD : 77.17 (+0.19%)
HRC : 79.97 (+1.34%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakest short term outlook on maintaining the current direction.

Longer term, the trend strength is Minimum. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Galectin Therapeutics Inc. is a drug development company engaged in the development new therapies for fibrotic disease and cancer. The Company uses its carbohydrate technology that targets galectin proteins, the key mediators of biologic and pathologic function. Galectin Therapeutics uses naturally occurring...

See More

Support & Resistance

2nd Resistance Point 2.57
1st Resistance Point 2.52
Last Price 2.47
1st Support Level 2.43
2nd Support Level 2.39

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.